Navigation Links
Randomized Controlled Trial Finds Masimo PVI Improves Fluid Management During Surgery
Date:8/31/2010

IRVINE, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI) announced today that a new randomized controlled trial published in Anesthesia & Analgesia shows that clinicians using Masimo Pleth Variability Index (PVI®) significantly improved fluid management and reduced lactate levels in patients during and after surgery, compared to patients managed by standard care without PVI(1).  Multiple previous studies(2,3,4) have shown that PVI predicts fluid responsiveness, defined as a significant increase in cardiac output after fluid administration, but this is the first published study to show that the use of PVI can improve patient management compared to a group of patients not managed with PVI.  

Although fluid administration is critical to optimizing patient status and enabling end organ preservation, unnecessary fluid administration is associated with increased morbidity and mortality.  Traditional invasive measurements such as central venous pressure (CVP) are not reliable in predicting whether a patient will benefit from fluid administration, and newer methods of predicting fluid responsiveness are invasive and/or costly. Masimo PVI provides clinicians with a noninvasive, continuous, and cost-effective measure in assessing whether patients will benefit from fluid administration to enable more personalized and targeted fluid therapy.

In the current study, researchers from the University Catholique de Louvain, St. Luc Hospital in Brussels, Belgium, randomized 82 patients undergoing abdominal surgery into two groups, a control group where fluid management was guided by standard care through CVP and clinician assessment, and the PVI group where fluid management was guided by standard care and PVI values from a Masimo Radical-7® Pulse CO-Oxime
'/>"/>

SOURCE Masimo Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
3. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
4. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
5. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
8. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
9. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
10. Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Echo Pharma Acquisition Limited ("Royalty Pharma") announced ... Acceptance Threshold from 90 percent to 50 percent of ... accordance with the terms of the Revised Offer Document ... Under the terms of the Increased Offer, Royalty ... ELN ) for $12.50 per share in cash. The ...
(Date:5/23/2013)... 2013 Nederland keurt als eerste ... geassocieerd met BPH Astellas Pharma ... Pharma Inc, gebaseerd in Tokyo ... dat het Nederlandse College ter Beoordeling van Geneesmiddelen (CBG) ... De handelsvergunning verleend voor VESOMNI is voor "de ...
(Date:5/22/2013)... LAGUNA HILLS, Calif. , May 22, 2013 /PRNewswire/ ... is developing a medical device that will help alleviate ... preeclampsia. APT,s targeted apheresis cartridge is expected to be ... a leading cause of maternal and fetal death. ... in the United States . It ...
Breaking Medicine Technology:Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 2Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 3Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 4Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia 2
... Conference Call Scheduled for 9:00 AM ET ... Dendreon Corporation (Nasdaq:,DNDN) announced today that it ... Phase 3, randomized, double-blind, placebo-controlled IMPACT,(IMmunotherapy for ... trial designed to assess the safety and ...
... that drinking polyphenol-rich 100% Concord grape,juice was not ... body,weight, CONCORD, Mass., Oct. 6 Regular ... cause significant weight gain,was not associated with changes ... according to new data presented at the 49th ...
Cached Medicine Technology:Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3
(Date:5/23/2013)... 23, 2013) Aortic arch pulse wave velocity, a ... of disease of the vessels that supply blood to ... the June issue the journal Radiology . ... functional information about vessel compliance that may help determine ... said Kevin S. King, M.D., assistant professor of radiology ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Applied PilotFish ... announced today that it has added support for the ... IDE, the eiConsole for Healthcare. In addition to the ... as LLP, FTP, and Web Services, it now offers ... Direct Protocol is a specification of the Direct ...
(Date:5/23/2013)... Elegance for a woman takes on so many ... her intrigue can often be found in the mystery of her ... soul is through her eyes. It is also true that ... is why the elegance of a woman can be found in ... more than any other time, utilize eyewear to not only compliment ...
(Date:5/23/2013)... Aero Fulfillment Services, a national provider of ... to be the sole fulfillment provider for Olivenol® plus ... Brad Cole, CEO New Wave Biosciences said, “We chose ... location, e-commerce experience with both of our key audiences ... that will expand as our distribution grows.” He ...
(Date:5/23/2013)... Each month Dwell magazine is filled with ... electric cars. Nowhere in America are these pages more scoured ... capital. Thankfully this June, Green Car Journal is bringing its ... Dwell on Design 2013 ( http://www.dwellondesign.com ), America’s ... days of Dwell on Design, June 21-22, attendees and media ...
Breaking Medicine News(10 mins):Health News:MRI-based measurement helps predict vascular disease in the brain 2Health News:PilotFish Expand’s Healthcare Integration Capabilities with Support for the New Direct Protocol in Its Latest Product Release 2Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2Health News:NewWave Biosciences Chooses Aero Fulfillment for e-Commerce Distribution of New Product to Reduce Inflammation 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5
... the lymph nodes also, according to a recent research, led ... immune response. // ,The dreaded disease is ... and the immature parasites travel to the animal's liver. Once ... liver cells and infect red blood cells, beginning the onset ...
... the teenaged girls in the UK are virtually starving themselves to ... Agency and Sugar magazine. // Some of these girls are reported ... 50 per cent always skip breakfast and do not know what ... they eat ‘as little as possible,’ while ten per cent said ...
... risk factors like blood pressure, age and medical history. Those who ... can be treated as outpatients, according to a publication in ... abrupt blockage of an artery due to a blood clot, or ... major health hazard. This is not fatal in the case of ...
... many as 20% of the men in the US suffer ... other diseases, including heart diseases. // The number of visits ... was introduced in 1998. The data available from the National ... S. Saigal and his colleagues. ,About 2,126 men ...
... that as many as 250,000 Scots are unable to access ... Health Department had drawn up an emergency care plan which ... as ?1.5 million has been allocated for this. The situation ... 10% of the population having to wait for a period ...
... a survey in 5 European countries on how women lead ... to find out whether women enjoyed the present life ... the work was funded by Economic and Social Research Council. ... have problems with their family life. ,Researchers found ...
Cached Medicine News:Health News:Malaria Can Develop In Lymph Nodes Also 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: